Oncoinvent Reaches 50% Recruitment Milestone in Phase 2 Ovarian Cancer Trial of Alpha-Emitting Radspherin
核心洞察
Oncoinvent (搜索) has enrolled 54 of 108 planned patients in its Phase 2 trial of Radspherin for peritoneal metastases (搜索) from ovarian cancer (搜索), reaching the 50% recruitment milestone.
Year-to-date recruitment of 28 patients in 2026 has already surpassed total enrollment for all of 2025, reflecting strong acceleration across ten active trial sites.
The randomized controlled trial compares progression-free survival between patients receiving a single intraperitoneal dose of Radspherin post-surgery plus chemotherapy versus standard of care alone.
Oncoinvent (搜索), a clinical-stage radiopharmaceutical company based in Oslo, Norway, announced on June 18, 2026 that its ongoing Phase 2 trial of Radspherin has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled, representing half of the planned trial population of 108 participants.
The trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin, a receptor-independent alpha-emitting therapy, in patients with peritoneal metastases (搜索) from ovarian cancer (搜索). The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone.
Accelerating Recruitment Momentum
Recruitment momentum has accelerated significantly in 2026. Eleven patients were enrolled in the first quarter, and 17 patients have been recruited in the second quarter to date — marking the highest recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025.
Four new sites have opened for recruitment in 2026, bringing the total to ten active hospitals across the United States, Spain, Norway, Belgium, the United Kingdom, and Italy. Further site activations are ongoing to support continued enrollment.
Leadership Commentary
"Reaching the halfway point for recruitment in our Phase 2 trial is an important milestone for Oncoinvent (搜索) and reflects the strong commitment of investigators and study sites," said Oystein Soug, CEO of Oncoinvent. "We are pleased to see the steps taken to accelerate recruitment translating into the strong enrollment momentum seen in 2026. Building on the encouraging safety profile and preliminary efficacy signals observed in earlier studies, we look forward to further evaluating Radspherin's potential to improve outcomes for patients with peritoneal metastases (搜索) from ovarian cancer (搜索), who have limited treatment options following surgery."
Radspherin: Mechanism and Earlier Clinical Data
Radspherin is designed as a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The therapy is administered following surgical removal of the primary tumor and visible metastases in the peritoneum, with the goal of preventing or delaying recurrence in the peritoneal cavity.
Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7 MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer (搜索) have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer (搜索) have been published in the Journal of Surgical Oncology and Frontiers in Medicine.
The radiopharmaceutical is broadly applicable to any cancer that spreads to the peritoneum, including ovarian, colorectal, and gastric cancers. Oncoinvent (搜索) highlights Radspherin's simplicity, excellent safety profile, seamless integration into existing surgical workflows, and cost-effective manufacturing as key differentiating features.
Next Steps
Interim data from the ongoing randomized, controlled Phase 2 ovarian cancer (搜索) trial is expected in 2026. Oncoinvent (搜索) was founded by the originators of Algeta and Xofigo, the latter of which was acquired by Bayer.